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Rationale: Previous studies have demonstrated that chronic obstructive pulmonary disease 
(COPD) causes increased mortality in the general population. But life expectancy and the years 
of life lost have not been reported.
Objectives: To quantify mortality, examine how it varies with age, sex, and other risk factors, 
and determine how life expectancy is affected.
Methods: We constructed mortality models using the Third National Health and Nutrition 
Examination Survey, adjusting for age, sex, race, and major medical conditions. We used these 
to compute life expectancy and the years of life lost.
Measurements and main results: Pulmonary function testing classiﬁ  ed patients as having 
Global Initiative on Obstructive Lung Disease (GOLD) stage 0, 1, 2, 3 or 4 COPD or restriction. 
COPD is associated with only a modest reduction in life expectancy for never smokers, but 
with a very large reduction for current and former smokers. At age 65, the reductions in male 
life expectancy for stage 1, stage 2, and stages 3 or 4 disease in current smokers are 0.3 years, 
2.2 years, and 5.8 years. These are in addition to the 3.5 years lost due to smoking. In former 
smokers the reductions are 1.4 years and 5.6 years for stage 2 and stages 3 or 4 disease, and in 
never smokers they are 0.7 and 1.3 years.
Conclusions: Persons with COPD have an increased risk of mortality compared to those who 
do not, with consequent reduction in life expectancy. The effect is most marked in current 
smokers, and this is further reason for smokers to quit.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease where 
airways in the lungs are damaged. It is a major cause of morbidity and mortality in the 
United States and around the world.1–8 In the United States, COPD was responsible 
for over 120,000 deaths in 2004 and is the only cause of death in the top ﬁ  ve to have 
been increasing since 1990.9 Prevalence estimates in the United States range from 10 
to 16 million adults, but the condition may be under-diagnosed.10,11 The overall attribut-
able morbidity and mortality from COPD may, therefore, be underestimated.
Risk factors for COPD include genetic factors and environmental exposures. The 
major exposures are tobacco smoke, occupational dusts and chemicals, and pollution.12 
In industrialized nations, tobacco smoke is the biggest risk factor, where up to 50% 
of long-term smokers will develop COPD,13 while in less industrialized nations it is 
exposure to air pollution.14 Conversely, of persons with COPD in the western world, 
roughly 50% have smoking as the underlying etiology.13 Symptoms generally emerge 
after age 40, but can manifest earlier.
Mannino and colleagues4 analyzed data from the First National Health and Nutrition 
Examination Survey (NHANES I), using a modiﬁ  ed version of the Global Initiative International Journal of COPD 2009:4 138
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for Chronic Obstructive Lung Disease (GOLD) criteria for 
COPD and other respiratory disease in that population. The 
authors reported all-cause mortality relative risks (RRs) 
for COPD based on multivariable models that controlled 
for smoking status, pack-year history, years since last 
regularly smoked, body mass index (BMI), and a number of 
demographic variables. The RRs ranged from 1.2 for mild 
COPD to 1.7 for severe. Some other studies also reported 
RRs based on severity.2,7,15,16 To our knowledge, however, 
no studies have reported life expectancies in COPD, or the 
years of life lost.
Our primary goal was to compute life expectancy and the 
years of life lost due to COPD. To do so we required quantiﬁ  -
cation of the excess mortality associated with COPD. We thus 
sought to calculate the associated excess death rates (EDRs) 
and RRs, and to investigate whether these varied by age, sex, 
race, education, smoking status, the presence of concomitant 
medical conditions, and time since evaluation. We were 
particularly interested in how the RRs varied with age, as we 
have found in other chronic conditions that it declines with 
age.17,18 Using the aforementioned results, we then computed 
life expectancies for the various groups, in order to determine 
the years of life lost due to COPD. As noted, these quantities 
have not been reported in the literature.
Methods
Study population
The Third National Health and Nutrition Examination Survey 
(NHANES III) was conducted 1988 to 1994 by the National 
Center for Health Statistics on a nationwide probability 
sample of 33,994 persons aged two months and older through 
interviews and direct physical examinations.19,20 To focus on 
the effects of COPD in an older population, we restricted 
attention to the 6,261 adults over age 50 who had a reliable 
or reproducible pulmonary test and smoking history (except 
as noted below). Of these persons, 3,555 were smokers or 
former smokers and 3,362 had pack-year history. Pipe or 
cigar smokers were counted as current or former smokers 
as appropriate, but we did not have pack year history on 
these persons.
Measurements
Examiners used either a dry rolling seal spirometer in the 
mobile examination center or a portable spirometer in the 
home examination to conduct pulmonary function testing. 
Testing procedures were based on the 1987 American 
Thoracic Society recommendation.21 Subjects performed 5 
to 8 forced expirations in order to obtain acceptable protocol 
curves. Predicted forced expiratory volume in one second 
(FEV1) was calculated using previously published prediction 
equations from the NHANES III data, stratiﬁ  ed by sex, age, 
and race.22–25 Persons were considered as having COPD only 
if conﬁ  rmed by pulmonary function testing. Otherwise they 
were assumed to have no lung disease (Normal) or GOLD 
stage 0 if they reported respiratory symptoms. The severity 
scale for COPD used by Mannino and colleagues4 and in the 
present study is shown in Figure 1.
Statistical analysis
Analyses were performed using the statistical package SAS 
9.1 for Windows (SAS Institute, Cary, NC).26 Kaplan–Meier 
survival curves were produced for various groups.27 Cox 
proportional hazards regression models were developed 
using the “PROC PHREG” procedure in SAS. These models 
provide hazard ratios (or, equivalently, RRs) for each 
potential mortality risk factor. The variables included in one 
or more of the multivariable regression models were: Age, 
sex, race, smoking status, pack-years of cigarette smoking, 
BMI, major medical conditions, and lung function (COPD) 
category. The models were used to compute mortality rates 
for various groups, including 65 year-old males with the 
given severities of COPD. The difference between a given 
rate and the corresponding general population (or other 
baseline) mortality rate is the EDR, which were computed 
for the various groups.
Life expectancies were computed for the same groups by 
using the above mortality rates to construct a life table.28–30 
A remaining issue was the imputation of some mortality 
rates. When the EDR was positive (increased risk compared 
with the general population), the assumption of proportional 
life expectancy (PLE)18,29 was used to obtain the mortality 
rates at older ages. In brief, this method assumes that the 
proportion of normal life expectancy for a given medical 
condition is the same at every age.18,29 For example, if the 
life expectancy in mild COPD is 90% of normal at age 50, 
then under PLE it would be 90% of normal at age 70 as well. 
When the EDR was negative, it was assumed to approach 
zero with age, much as persons in above-average health 
revert to the mean.
Results
The mean duration of follow-up of the 6,261 persons studied 
was 7.9 years (with standard deviation 2.8 years), and there 
were 1,873 deaths. Table 1 shows the baseline demographic 
characteristics of the cohort. Overall, the percentages of 
persons with spirometric evidence of COPD were: GOLD International Journal of COPD 2009:4 139
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stage 1: 16%, GOLD stage 2: 12%, GOLD stage 3 or 4: 3%, 
and restriction: 8%.
Figures 2–5 show the Kaplan–Meier survival curves 
based on severity of COPD, both for the entire population and 
stratiﬁ  ed by smoking status. In all cases, any lung function 
impairment was associated with an increased risk of death.
These curves were used to compute the (crude) EDRs 
associated with COPD that are shown in Table 2. For 
example, amongst smokers, the 10-year survival probability 
persons with no lung disease was 75%, compared with 65% 
for persons with COPD symptoms, 63% for stage 1, 58% 
for stage 2, and approximately 15% for stage 3 or 4. The 
associated annual mortality rate over the 10-year period for 
smokers with no lung disease is thus –ln(0.75)/10 = 0.0288. 
For stages 1, 2, and 3 or 4 COPD, the rates are 0.0462, 0.0545, 
and 0.1897, respectively. Thus, the EDR over the 10-year 
period for smokers with stage 1 COPD, compared with 
smokers with no lung disease, is 0.0462 − 0.0288 = 0.0174. 
For stages 2 and 3 or 4 COPD, the EDRs are higher, 0.0257 
and 0.1609, respectively. EDRs for all 24 groups are shown 
in Table 2. It is important to note that these are crude EDRs, 
unadjusted for any possible confounding factors.
The EDRs implicit in the “All” group in Figure 2 of 
Mannino and colleagues4 are roughly one-third lower than 
those reported in Table 2 here. The reason is that the EDR 
increases with age, and the Mannino and colleagues study 
population was signiﬁ  cantly younger than the population 
used here: unlike the present study, half their population was 
under age 50 at the start of follow-up.
Additional analyses (not shown) indicated that persons 
with COPD, compared to those without lung disease, tended 
to be older and male, and of course were much more likely 
to be smokers. It is important to note that the survival curves 
in Figures 2–5 were not adjusted for any of the covari-
ates. Thus, the EDRs given in Table 2 may be confounded 
with the effects of these covariates. We wished to obtain 
an unconfounded (or pure) estimate of the EDRs or RRs 
associated with COPD. For this we required multivariate 
Classification 
Stage 0  (Symptoms Only)    
FEV1/FVC < 70%
FEV1 ≥ 80% predicted
With or without chronic symptoms   
FEV1/FVC < 70%
50% ≤ FEV1< 80% predicted
With or without chronic symptoms      
FEV1/FVC < 70%
30% < FEV1< 50% predicted
With or without chronic symptoms 
    
Restrictive lung disease (RLD)  
Stage 1 (Mild)
Stage 2 (Moderate)
FEV1/FVC ≥70%
FVC < 80% predicted 
Stage
Normal spirometry
Presence of respiratory symptoms  
Stage 3 or 4 (Severe)
Figure 1 Seventy scale for COPD.
Notes: Those who were diagnosed by a physician as having chronic bronchitis, emphysema, or asthma but did not have COPD or RLD according to the above criteria were 
classiﬁ  ed as GOLD stage 0 (if they reported symptoms) or Normal (if they reported no symptoms). Persons who had a positive response to (a) having a cough for three 
consecutive months out of the year, (b) phlegm ﬁ  rst-thing in the morning three consecutive months out of the year, or (c) wheezing in the past 12 months, were considered 
as having GOLD stage 0 if their pulmonary function testing did not indicate COPD or RLD.
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, forced expiratory volume in one second; 
FVC, forced vital capacity; RLD, restrictive lung disease.International Journal of COPD 2009:4 140
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Table 1 Demographics and description of key variables. All ﬁ  gures are column percentages except for counts (n, died) and age
All Current smoker Former smoker Never smoker
n 6,261 1,294 2,261 2,706
Died 1,873 413 751 709
Age (mean ± SD)
 Male 67 ± 10 64 ± 9 69 ± 10 68 ± 11
 Female 68 ± 11 63 ± 8 67 ± 10 69 ± 11
 Male 48% 62% 67% 24%
 Caucasian,  non-Hispanic 57% 51% 64% 56%
  No college education 77% 81% 75% 78%
COPD
  Stage 3 or 4 3% 7% 4% 1%
 Stage  2 12% 22% 14% 6%
 Stage  1 16% 18% 19% 12%
 Stage  0 14% 14% 14% 13%
 RLD 8% 7% 7% 9%
 Normal 48% 33% 43% 58%
Smoking status
 Smoker 21% 100%
 Former  smoker 36% 100%
 Never  smoker 43% 100%
Pack-years
 High  (60) 10% 17% 18%
 Medium  (30–60) 16% 34% 25%
 Low  (1–30) 27% 44% 50%
BMI
 Underweight  (18.5) 2% 5% 1% 2%
  Normal weight (18.5–25) 31% 40% 28% 30%
 Overweight  (25–30) 40% 36% 43% 38%
 Obese  (30) 27% 19% 28% 30%
Medical conditions (% yes)
 Diabetes 14% 10% 16% 14%
 Hypertension 43% 37% 44% 46%
 CHF 7% 6% 9% 6%
 Stroke 6% 5% 7% 5%
 MI 9% 9% 13% 7%
  Cancer (other than skin) 7% 5% 8% 7%
Abbreviations: BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; RID, restrictive lung disease.
statistical methods, such as the Cox proportional hazards 
regression model.
Cox models were used to adjust for age, sex, race, 
education, smoking status, smoking history, weight, and major 
medical conditions. The variables, their various levels, and the 
associated relative risks of mortality are shown in Table 3.
As expected, the relative risks associated with COPD 
increased with increasing severity of COPD. In all cases the 
relative ordering of severity was preserved in the resulting 
RRs. However, as can be seen, the stage 1 group had a relative 
risk that, in 3 of the 4 cases, was actually less than that of the 
reference group (stage 0), though the differences were neither 
practically nor statistically signiﬁ  cant. We return to this issue 
in the discussion. Those with restrictive lung disease (RLD) 
or symptoms of COPD, but no formal diagnosis, both had 
uniformly increased risk of death compared with those with 
no lung disease.
Other analyses (not shown), using models that (a) 
accounted for only age, sex, and COPD, and (b) were based 
on different subsets of data, yielded similar results. Separate International Journal of COPD 2009:4 141
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analysis of pipe and cigar smokers (not shown) revealed that 
their mortality risk was similar to that of smokers (RR = 1.0), 
and higher than that of former smokers (RR = 1.1).
Further analyses (not shown) revealed that the effect 
of COPD did not appear to vary by sex, race, or college 
education. That is, there were no signiﬁ  cant interactions. But it 
did vary by age, as we hypothesized, with older persons having 
a lower RR than younger persons (results not shown). This 
was true for those with stage 2 and 3 or 4 COPD, and amongst 
current, former, and never smokers, with one exception (it did 
not hold for the former smokers with moderate COPD). We 
comment further on this issue in the discussion.
The last row of Table 3 shows the mortality rate for the 
composite baseline group: female, age 50–59, non-Caucasian, 
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Figure 2 Kaplan–Meier survival curves of all 6,261 participants age 50 and over in NHANES III, stratiﬁ  ed by lung function impairment.
Figure 3 Kaplan–Meier survival curves of 1,294 current smokers age 50 and over in NHANES III, stratiﬁ  ed by lung function impairment.
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college education, no lung disease, never smoker (ﬁ  rst model 
only), low pack-years of smoking (models 1–3 only), normal 
weight, and no other medical conditions. As can be seen, 
even “healthy” current smokers, with low pack-years, have 
a baseline mortality rate that is much higher than the never 
smokers (0.0103 vs. 0.0041). By comparison, we note that 
the corresponding annual mortality rates at age 55 for the 
United States female general population28 and the insured 
population (at time of underwriting)31 are 0.0048 and 0.0009, 
respectively. That is, the best group contemplated by the 
models is slightly better than the general population, but does 
not have mortality as low as the recently insured (who have 
additionally demonstrated normal blood work, urinalysis, 
and electrocardiogram).
The RRs from Table 3 can also be used to compute the 
mortality rate for any combination of levels of the covariates 
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Figure 4 Kaplan–Meier survival curves of 2,261 former smokers age 50 and over in NHANES III, stratiﬁ  ed by lung function impairment.
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Figure 5 Kaplan–Meier survival curves of 2,706 never smokers age 50 and over in NHANES III, stratiﬁ  ed by lung function impairment.International Journal of COPD 2009:4 143
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in the model. For example, using the “All” group, the 
mortality rate for a 75 year-old male, Caucasian, no college 
education, no lung disease, smoker, medium pack-years, 
normal weight, with no medical conditions is 0.0060 * 1.3 * 
1.0 * 1.2 * 4.5 * 1.0 * 1.5 * 1.1 * 1.0 = 0.0695.
We used the model of Table 3 to compute mortality rates 
for various groups of 65-year-old Caucasian males with col-
lege education, normal weight, and no medical conditions 
(for the smoking groups we assumed low pack-years, and 
for the “all” group we assumed “never smoker”). These rates 
are shown in Table 4.
We computed the EDRs implicit in Table 4 by subtracting 
from each the US male general population mortality rate at 
age 65 (0.0186). The resulting EDRs are shown in Table 5. 
As can be seen, these are smaller than the EDRs of Table 2 
for the “all”, former, and never groups, and higher for some 
of the smoking groups. Otherwise, there is no clear pattern. 
That the EDRs would differ between the tables is under-
standable, as the former are crude (or possibly confounded) 
while the latter are at least partially adjusted for the factors 
in the models of Table 3 (that is, computed after controlling 
for the factors in the models, including having no medical 
conditions).
Implicit in Table 5 is the observation that the EDRs 
for COPD are higher for smokers than for nonsmokers or 
never smokers. For example, within current smokers, the 
EDR for stage 3 or 4 COPD compared with mild COPD is 
0.0601 − 0.0109 = 0.0492 whereas for never smokers it is 
only 0.0010 − (−0.0077) = 0.0087. This is one example of 
“super-additivity”, where the risk associated with two factors 
(here, smoking and COPD) is greater than the sum of the 
separate risks associated with these factors. Super-additivity 
is also seen, for example, with respect to smoking and dia-
betes. We return to this issue in the discussion.
We next used the rates of Table 4 to compute life 
expectancies for the 24 (male) groups. The indicated rates 
Table 2 Excess deaths rates from Figures 2–5, relative to persons 
with no lung disease
Group Smoking status
All Current Former Never
Normal Reference Group
Stage 0 (Symptoms only) 0.0098 0.0143 0.0128 0.0055
Restrictive lung disease 0.0174 0.0069 0.0292 0.0190
Stage 1 0.0190 0.0174 0.0223 0.0207
Stage 2 0.0310 0.0257 0.0366 0.0257
Stage 3 or 4 0.0884 0.1609 0.1484 0.0707
Table 3 Relative risks from multivariable Cox proportional hazards 
regressions models
Variablea Smoking status
All persons Current Former Never
Male 1.3 1.6 1.2 1.2
Caucasian 1.0 0.9 1.0 1.0
No college education 1.2 0.9 1.3 1.2
Age
 50–59 1.0 1.0 1.0 1.0
 60–69 2.0 2.1 1.9 2.2
 70–79 4.5 3.8 4.2 6.0
 80+ 11.6 8.6 9.5 17.9
COPD
  Stage 3 or 4 2.6 2.7 3.0 1.8
 Stage  2 1.4 1.4 1.5 1.5
 Stage  1 0.9 1.0 0.9 0.9
 Stage  0 1.2 1.4 1.2 1.1
 RLD 1.3 1.3 1.4 1.2
 Normal 1.0 1.0 1.0 1.0
Smoking status
 Smoker 1.5
 Former  Smoker 1.0
 Never  Smoker 1.0
Pack-years history
 High 1.3 1.3 1.2
 Medium 1.1 1.2 1.1
 Low 1.0 1.0 1.0
BMI
 Underweight 1.7 1.8 2.0 1.5
 Normal  weight 1.0 1.0 1.0 1.0
 Overweight 0.9 0.8 0.9 0.9
 Obese 0.8 0.7 0.8 0.8
Medical conditions
 Diabetes 1.7 1.8 1.5 2.0
 Hypertension 1.2 1.4 1.1 1.3
 CHF 1.3 1.2 1.2 1.5
 Stroke 1.4 1.1 1.6 1.4
 MI 1.2 1.4 1.3 1.0
 Cancer 1.4 1.2 1.3 1.6
Baseline mortality rateb 0.0060 0.0103 0.0069 0.0041
Notes: aThe respective reference groups for these relative risks are persons who are: 
female, non-Caucasian, college education, aged 50–59, no lung disease, never smoker 
(for the ﬁ  rst model), low pack-years (for the ﬁ  rst three models), normal weight, and 
without any of the speciﬁ  ed medical conditions. bThis the mortality rate for persons 
in the reference group described immediately above. It is computed by setting the 
values of the covariates (variables) in the respective models equal to zero.
Abbreviations: BMI, body mass index; CHF, congestive heart failure; COPD, chronic 
obstructive pulmonary disease; MI, myocardial infarction; RID, restrictive lung disease.
were used for age 65. Because we found that the RR decreases 
with age (and the EDR increases with age), an assumption 
of constant EDR or constant RR with age was not war-
ranted. Of course we could have used the model of Table 3 International Journal of COPD 2009:4 144
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to compute mortality rates at all ages. Yet, as just noted, the 
RR decreases with age. Thus, using model-based rates at all 
ages would overestimate mortality and, thus, underestimate 
life expectancy. We opted to take a middle position: the use 
of proportional life expectancy (PLE).18,29 It can be shown 
that this method has implications for the EDR at every 
age,18,29 upon which it follows that our approach here could 
rely equally on the rates of Table 4 or the EDRs of Table 5. 
For females, the corresponding mortality rates are shown in 
Table 6, and the EDRs in Table 7.
Life expectancies based on the rates of Tables 4 and 5 
are given in Table 8. As can be seen, the best group – never 
smokers with no signiﬁ  cant lung disease and no medical 
conditions – have a life expectancy of 17.8 additional years. 
Not surprisingly, this is higher than the corresponding ﬁ  gure 
in the United States general population (16.8 years). By 
contrast, current smokers with no lung disease have a life 
expectancy of 14.3 years, or 3.5 years lower than 17.8, similar 
to the ﬁ  nding of Doll and colleagues.32 As expected, the 
presence of COPD further decreases the life expectancy.
Current smokers with stage 1 COPD have a life expectancy 
of 14.0 years, or 0.3 years lower. Smokers with stage 2 COPD 
have a life expectancy of 12.1 years, or 2.2 years lower. 
Those with stage 3 or 4 COPD have a life expectancy of 
8.5 years, or 5.8 years lower. Former smokers lose 0.5 years 
for smoking, 1.4 additional years for stage 2 COPD and 
5.6 additional years for stage 3 or 4 COPD, compared with 
otherwise similar persons who do not have lung disease. 
By contrast, never smokers lose only 0.7 years for stage 2 
COPD and 1.3 years for stages 3 or 4 COPD. The two cases 
with an increase in life expectancy for COPD compared 
with no lung disease (stage 1 COPD in former and never 
smokers) are undoubtedly both due to the comparatively 
large standard errors (not shown) in the respective stage 1 
parameter estimates of Table 3. The standard errors are much 
smaller for the other parameters. In sum, the years of life 
lost due to stages 2, 3, or 4 COPD is signiﬁ  cant in current 
and former smokers, and modest in nonsmokers and those 
with stage 1 COPD.
Table 9 shows the corresponding values for females (using 
the mortality rates in Table 6 or the EDRs in Table 7). As 
with males, the reductions in life expectancy are signiﬁ  cant 
for both smokers and those with stage 2, 3, or 4 COPD. For 
example, never smokers with stage 3 or 4 COPD lose 1.9 years 
of life, while smokers with stage 3 or 4 COPD lose 9.0 years, 
or 44% of the 20.3 years that obtains for a never smoker with 
no lung disease. The life expectancies in Tables 8 and 9 are 
shown graphically in Figures 6 and 7.
Table 4 Mortality rates for otherwise healthy 65-year-old 
Caucasian males based on the models of Table 3
Group Smoking status
All Current Former Never
Normal 0.0153 0.0295 0.0151 0.0109
Stage 0 (Symptoms only) 0.0179 0.0400 0.0176 0.0120
Restrictive lung disease 0.0204 0.0383 0.0216 0.0132
Stage 1 0.0143 0.0308 0.0140 0.0096
Stage 2 0.0217 0.0424 0.0221 0.0164
Stage 3 or 4 0.0397 0.0787 0.0449 0.0196
Table 5 Excess death rates for otherwise healthy 65-year-old 
Caucasian males, computed as Table 4 less the mortality rates for 
males aged 65 in the general population (0.0186)
Group Smoking status
All Current Former Never
Normal −0.0033 0.0109 −0.0035 −0.0077
Stage 0 (Symptoms only) −0.0007 0.0214 −0.0010 −0.0066
Restrictive lung disease 0.0018 0.0197 0.0030 −0.0054
Stage 1 −0.0043 0.0122 −0.0046 −0.0090
Stage 2 0.0031 0.0238 0.0035 −0.0022
Stage 3 or 4 0.0211 0.0601 0.0263 0.0010
Table 6 Mortality rates for otherwise healthy 65-year-old 
Caucasian females based on the models of Table 3
Group Smoking status
All Current Former Never
Normal 0.0119 0.0190 0.0125 0.0089
Stage 0 (Symptoms only) 0.0138 0.0258 0.0146 0.0098
Restrictive lung disease 0.0158 0.0247 0.0179 0.0107
Stage 1 0.0111 0.0198 0.0116 0.0078
Stage 2 0.0168 0.0273 0.0183 0.0133
Stage 3 or 4 0.0307 0.0507 0.0373 0.0159
Table 7 Excess death rates for otherwise healthy 65-year-old 
Caucasian females, computed as Table 6 less the mortality rates 
for females aged 65 in the general population (0.0120)
Group Smoking status
All Current Former Never
Normal −0.0001 0.0070 0.0005 −0.0031
Stage 0 (Symptoms only) 0.0018 0.0138 0.0026 −0.0022
Restrictive lung disease 0.0038 0.0127 0.0059 −0.0013
Stage 1 −0.0009 0.0078 −0.0004 −0.0042
Stage 2 0.0048 0.0153 0.0063 0.0013
Stage 3 or 4 0.0187 0.0387 0.0253 0.0039International Journal of COPD 2009:4 145
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As noted, the models of Table 3 can be used to compute 
mortality rates, and thus life expectancies, for any combinations 
of the covariates. We could thus construct tables similar 
to Tables 8 and 9 for persons aged 55 or 75, or those with 
diabetes.
Discussion
Although the number of persons with COPD seems unusu-
ally high compared to other published reports (31% vs 
15%),12 our population was comparatively older, and oth-
ers have noted that COPD is generally underdiagnosed in 
the general population.10–11 Persons who exhibit no signs 
or symptoms of abnormal lung function are unlikely to be 
tested by spirometry, and thus are unlikely to be diagnosed 
with COPD. Another possible reason for the high number 
of persons with COPD could be related to the fact that 
persons who are older will naturally have a lower lung 
function compared to their younger counterparts. While 
Hankinson and colleagues22 attempted to account for this 
in their regression model for adults, it is possible that a 
single equation for all adults may not properly estimate the 
predicted FEV1 and forced vital capacity (FVC) at older 
ages. Thus, persons who actually might have normal lung 
function for their age might incorrectly be placed into the 
category of mild COPD. The effect of this is to dilute the 
relative risks for older persons with mild COPD, and in fact 
may account for the nonsigniﬁ  cant relative risk for mild 
COPD that we found.
Mannino and colleagues4 reported a relative risk of 1.2 
for mild COPD. This was higher than the RRs we found 
(which were very close to 1.0). Their data (NHANES I) 
spanned 30 years of follow-up, while ours (NHANES III) 
spanned only 12. Perhaps, in the intervening 18 years, persons 
with mild COPD went on to develop more serious COPD. 
Hoogendern and colleagues33 studied the issue of COPD 
progression. They reported annual transition rates from mild 
to moderate COPD of 1.8%, 2.1% and 2.5% for nonsmokers, 
former smokers, and current smokers, respectively. For 
moderate to severe COPD the rates were 3.0%, 3.4%, and 
3.7%, respectively. Over a 12-year period, therefore, at least 
22% [= 100% – (100% − 2%)^12] would progress, and 
therefore be subject to an increased relative risk.
The excess risk in COPD increases with the severity of 
COPD. These ﬁ  ndings have been replicated across several 
databases, and by many research groups. We comment here 
on four such studies.
1.  Lee and colleagues,15 in analyzing the Health and 
Retirement Survey data, reported an odds ratio of 2.3 for 
persons with lung disease even after adjusting for age, 
sex, co-morbidities, and functional measures (bathing, 
managing ﬁ  nances, etc). Our values are mostly lower, 
likely due to our study population being older (see 
discussion below about the effect of advancing age).
2.  Ekberg-Aronsson and colleagues2 reported relative risks 
by gender and smoking status. They found relative risks 
of 2.4 and 3.6 for male smokers in the GOLD stage 3 or 
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Figure 6 Male life expectancy at age 65, stratiﬁ  ed by smoking status and severity of COPD (See Table 8).International Journal of COPD 2009:4 146
Shavelle et al
4 categories but who otherwise had no other co-morbidity. 
These RRs are higher than those we reported, but this is 
primarily due to the lower baseline mortality rate in their 
study. When we restricted attention to similar groups, we 
found similar results (not shown).
3.  Celli and colleagues16 used a different measure of COPD, 
the BODE index, which is a “multidimensional grading 
system that assessed the respiratory, perceptive, and 
systemic aspects of COPD that would better categorize 
the illness and predict the outcome than does the FEV1 
alone.” The index includes consideration of BMI, airﬂ  ow 
obstruction (based on predicted FEV1), dyspnea, and 
exercise capacity to determine classiﬁ  cation of severity 
in COPD. The authors found a 32% increased risk of 
death for each point increase in the index.
4. Singer7 compared the results of Celli and colleagues16 
to three older studies. Dividing the BODE index into 
quartiles, he found mortality ratios of 1.41, 2.76, 3.74, and 
8.29. He concluded that while FEV1 might be the strongest 
predictor of mortality, the other three factors (BMI, severity 
of dyspnea, and exercise capacity) were sufﬁ  ciently able to 
reﬁ  ne the levels of excess mortality. He also concluded that 
the BODE index may be a useful predictor in determining 
the statistical likelihood of survival in populations that 
have all four of the index measures. He noted, however, 
that in most cases the severity of dyspnea and exercise 
capacity are not available.
It is well known that COPD reduces life expectancy. As 
was documented here, the reduction is signiﬁ  cant for those 
with severe disease (GOLD State 3 or 4) and for smokers.
The new ﬁ  ndings reported here are the relative risks of 
Table 3, the mortality and excess death rates of Tables 4–7, 
and the life expectancies of Tables 8 and 9. The latter were 
used to document the years of life lost due to COPD and/or 
smoking. We also found (1) that the relative risk appears to 
decrease with age, and (2) the presence of super-additivity. 
We now comment on these latter two issues.
As is well known, once the schedule of age-speciﬁ  c 
mortality rates is known, a life table can be constructed and 
the life expectancy determined.29,30 It might seem reasonable, 
then, to use the model shown in Table 3 to calculate mortality 
rates for any combination of factors, especially for persons 
with COPD. To do so would overlook two issues, however.
First, the RRs of Table 3 apply to all combinations of 
the risk factors, and do not appear to vary signiﬁ  cantly by 
sex, race, education, and so on. But, as we have shown, 
they do vary by age. Thus, the relative risks reported in the 
Table are truly average RRs over the age-span. It might be 
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Figure 7 Female life expectancy at age 65, stratiﬁ  ed by smoking status and severity of COPD (See Table 9).
Table 8 Life expectancies for otherwise healthy 65-year-old 
Caucasian males, based on the rates in Tables 4 and 5. See also 
Figure 6
Group Smoking status
All Current Former Never
Normal 17.2 14.3 17.3 17.8
Stage 0 (Symptoms only) 16.9 12.5 16.9 17.7
Restrictive lung disease 16.3 12.7 16.0 17.5
Stage 1 17.4 14.0 17.4 18.0
Stage 2 16.0 12.1 15.9 17.1
Stage 3 or 4 12.5 8.5 11.7 16.5International Journal of COPD 2009:4 147
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reasonable, therefore, to assume that the relative risk applies 
at the average follow-up age (68 + 12/2), with possibly an 
additional offset to account for the variability.34,35
Second, one must specify the severity of COPD. As we 
have noted above, this cannot be assumed to remain static 
over the lifetime. A plausible simplifying assumption might 
be to assume that the EDR for the given severity applies at 
the initial age, and that this EDR increases in some fashion 
with age.18,29
The results shown in Tables 3, 5, and 7 conﬁ  rm that the 
effect of COPD is super-additive with respect to smoking. 
That is, the extra risk due to COPD is higher in smokers than 
in nonsmokers. The effect is also super-additive with respect 
to age, as the EDR (but not RR) increases with age.
Life insurance underwriters implicitly assume super-
additivity whenever they apply the same RR (or rating) to a 
smoker that they would to a nonsmoker. With a higher baseline 
mortality rate for smokers, the resulting EDR for the condition to 
be rated will be larger than the EDR for nonsmokers. If it is true 
that smoking increases the mortality effect of every risk factor 
(such as COPD), then this assumption appears reasonable.
It is important to note that a multiplicative model such as 
the Cox proportional hazards regression model is predicated 
upon super-additivity (actually, it assumes that the hazards 
are multiplicative, rather than additive). Further discussion is 
beyond the scope of the present article, but we hope to soon 
report on this issue in more detail.
As we have seen, COPD is associated with increased 
mortality and, thus, with reduced life expectancy. Those with 
stage 1 or 2 COPD lose at most a few years of life expectancy 
at age 65 compared with persons with no lung disease, in 
addition to any years lost due to smoking. But current smokers 
with stage 3 or 4 COPD lose about six years of life expectancy, 
in addition to the almost four years lost due to smoking.
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